🇺🇸 Cefazolin for Injection in United States

31 US adverse-event reports

Marketing authorisation

FDA

  • Status: approved

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

Most-reported reactions

  1. Hypoprothrombinaemia — 5 reports (16.13%)
  2. Urticaria — 5 reports (16.13%)
  3. Vitamin K Deficiency — 4 reports (12.9%)
  4. Drug Ineffective — 3 reports (9.68%)
  5. Dyspnoea — 3 reports (9.68%)
  6. Off Label Use — 3 reports (9.68%)
  7. Blood Creatinine Increased — 2 reports (6.45%)
  8. Blood Potassium Decreased — 2 reports (6.45%)
  9. Blood Pressure Decreased — 2 reports (6.45%)
  10. Bronchospasm — 2 reports (6.45%)

Source database →

Cefazolin for Injection in other countries

Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.

Frequently asked questions

Is Cefazolin for Injection approved in United States?

Yes. FDA has authorised it.

Who is the marketing authorisation holder for Cefazolin for Injection in United States?

University of Michigan is the originator. The local marketing authorisation holder may differ — check the official source linked above.